P-glycoprotein levels predict poor outcome in patients with osteosarcoma

Clinical Orthopaedics and Related Research

Volumn 373, Issue , 2000, Pages 11-17

  Hornicek, Francis J ^a,b   Gebhardt, Mark C ^a   Wolfe, Michael W ^a   Kharrazi, F Daniel ^a   Takeshita, Hideyuki ^a   Parekh, Selene G ^a   Zurakowski, David ^a   Mankin, Henry J ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; GLYCOPROTEIN P; METHOTREXATE; PHENOTHIAZINE DERIVATIVE;

ADOLESCENT; ADULT; AGED; BONE BIOPSY; BONE TUMOR; CANCER STAGING; CANCER SURVIVAL; CHILD; CLINICAL TRIAL; CONFERENCE PAPER; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; MULTIDRUG RESISTANCE; OSTEOSARCOMA; PHASE 1 CLINICAL TRIAL; POSTOPERATIVE CARE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

EID: 0034002172     PISSN: 0009921X     EISSN: 15281132     Source Type: Journal    
DOI: 10.1097/00003086-200004000-00003     Document Type: Conference Paper

References (18)

1. Bacci G, Picci P, Mercuri M, Bertoni F, Ferrari S: Neoadjuvant chemotherapy for high grade malignant fibrous histiocytoma of bone. Clin Orthop 346:178-189, 1998.
2. Baldini H, Scotlandi K, Barbanti-Brodano G, et al: Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. N Engl J Med 333:1380-1385, 1995.
3. Breslow NE, Day NE: Statistical Methods in Cancer Research. The Analysis of Case Control Studies. Vol 1. Lyon, France, IARC Publications 200-205, 1980.
4. Chan HSL, Thorner PS, Haddad G, Ling V: Immunohistochemical detection of P-glycoprotein: Prognostic correlation in soft tissue sarcoma of childhood. J Clin Oncol 8:689-704, 1990.
5. Cordon-Cardo C, O'Brien JP, Boccia J, Casals D, Bertino JR: Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 38:1277-1287, 1990.
6. Cox DR: Regression models and life tables. J Royal Stat Soc B 43:187-220, 1972.
7. Cox DR, Oakes D: Analysis of Survival Data. New York, Chapman and Hall 50-56, 1984.
8. Goorin A, Strother D, Poplack D, et al: Safety and efficacy of 1-leucovorin rescue following high dose methotrexate for osteosarcoma. Med Pediatr Oncol 24:362-377, 1995.
9. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958.
10. Kunikane H, Zalupski MM, Ramachandran C, et al: Flow cytometric analysis of P-glycoprotein expression and drug efflux in human soft tissue and bone sarcomas. Cytometry 30:197-203, 1997.
11. Posl M, Amling M, Grahl K, et al: P-glycoprotein expression in high grade central osteosarcoma and normal bone cells. An immunohistochemical study. Gen Diagn Pathol 142:317-325, 1997.
12. Rosier RN, O'Keefe RJ, Teot LA, et al: P-glycoprotein expression in cartilaginous tumors. J Surg Oncol 65:95-105, 1997.
13. Sridhar KS, Krishan A, Samy TSA, et al: Prochlorperazine as a doxorubicin - efflux blocker: Phase I clinical and pharmacokinetics studies. Cancer Chemother Pharmacol 31:423-430, 1993.
14. Takeshita H, Gebhardt MC, Springfield DS, Kusuzaki K, Mankin H: Experimental models for the study of drug resistance in osteosarcoma: P-glycoprotein-positive, murine osteosarcoma cell lines. J Bone Joint Surg 78A:366-375, 1996.
15. Terek RM, Schwartz GK, Devaney K, et al: Chemotherapy and P-glycoprotein expression in chondrosarcoma. J Orthop Res 16:585-590, 1998.
16. Weinstein RS, Kuszak JR, Kluskens JF, Coon JS: P-glycoproteins in pathology: The multidrug resistance gene family in humans. Hum Pathol 21:34-48, 1990.
17. Wunder JS, Bell RS, Bull SB, et al: MDR1 gene expression and outcome in osteosarcoma: A prospective, international, multicenter study. Orthop Res Soc 44:564, 1998. (Abstract).
18. Wunder JS, Bell RS, Wold L, Andrulis IL: Expression of the multidrug resistance gene in osteosarcoma: A pilot study. J Orthop Res 11:396-403, 1993.